{"entity":{"id":"nct07711002","kind":"trial","name":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07711002 as not yet recruiting, last updated 2026-07-17. Enrolment is 1330 planned participants, an estimate. Interventions: Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone. Primary measures include Radiographic progression-free survival (rPFS). No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07711002","url":"https://clinicaltrials.gov/study/NCT07711002"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07711002","phase":"3","setting":"A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05","sponsor":"AstraZeneca","started":"2026-10-01","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07711002/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}